ARTICLE DOWNLOAD

Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis

10.00$
ARTICLE DOWNLOAD

Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis

10.00$

Masatoshi Kanayama, Masataka Mori, Hiroki Matsumiya, Akihiro Taira, Shinji Shinohara, Taiji Kuwata, Naoko Imanishi, Kazue Yoneda, Koji Kuroda & Fumihiro Tanaka 

Abstract

Purpose

To assess the efficacy and feasibility of perioperative pirfenidone treatment (PPT) in lung cancer patients with idiopathic pulmonary fibrosis (IPF).

Methods

The subjects of this retrospective review were 100 patients diagnosed with IPF, who underwent surgical resection for primary lung cancer between January 2011 and April 2018 at our institution. We compared the clinical outcomes of patients treated with pirfenidone (PPT group; n = 28) and those of patients not treated with pirfenidone (non-PPT group; n = 72).

Results

The Japanese Association for Chest Surgery (JACS) risk score was significantly higher in the PPT group (p = 0.020, 10.9 vs. 9.4); therefore, we subdivided the groups based on JACS risk score. In the low-risk group, the incidence of postoperative acute exacerbation (AE) both within the postoperative day (POD) 30 and 90 was 0.0% (0/6) and 6.5% (2/31) in the PPT and non-PPT groups, respectively (p = 0.522). In the intermediate/high-risk group, the incidence of postoperative AE was 4.5% (1/22) and 19.5% (8/41) within POD 30 (p = 0.106) and 4.5% (1/22) and 24.4% (10/41) within POD 90 (p = 0.048) in the PPT and non-PPT groups, respectively. No serious pirfenidone-related complications were observed.

Conclusions

Based on our findings, PPT is an effective and feasible prophylactic treatment to reduce postoperative AE.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s00595-019-01923-5